Research News

Breast cancer research takes a significant stride forward as Professor Semin Lee and his research team from the Department of Biomedical Engineering at UNIST, in collaboration with Professor Ji-Yeon Kim and Professor Young-Hyuck Im from the Division of Hematology-Oncology at Samsung Medical Center in Seoul, delves into the exploration of triple negative apocrine carcinoma. This rare breast cancer subtype has garnered attention due to its unique genetic characteristics and improved prognosis when compared to other forms of triple-negative breast cancer (TNBC).

A study  led by Columbia obstetricians has shown that a new intrauterine device can rapidly control postpartum hemorrhage, a major cause of severe maternal morbidity and death, in real-world situations.

An LSU Health New Orleans research study led by Siqiong June Liu, PhD, Professor of Cell Biology and Anatomy, has found that cerebellar inhibitory interneurons are essential for fear memory, a type of emotional memory formation. Inhibitory interneurons within the cerebellar circuitry act as gatekeepers and control the output of the cerebellar cortex. The formation of fear memory requires the activity of these interneurons.

Through study findings published Friday in Cell Reports, a team of scientists at VCU Massey Cancer Center discovered a previously unknown interaction between proteins that is responsible for supplying energy to tumor cells and could hold significant implications for the development of future treatments for colon cancer.

New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has found that depression and the risk of depression are linked to different inflammatory proteins in boys and girls.

When inflammation occurs in the body a host of proteins are released into the blood called cytokines. Previous research has shown that higher levels of cytokines are associated with depression in adults, but little is known about this relationship in adolescence.

AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.

Scientists from Queen Mary University of London have discovered two new genes that cause head and neck cancer patients to be resistant to chemotherapy, and that silencing either gene can make cancer cells previously unresponsive to chemotherapy subsequently respond to it.

The two genes discovered actively ‘work’ in most human cancer types, meaning the findings could potentially extend to other cancers with elevated levels of the genes.

Researchers at the Francis Crick Institute have identified stem cells in the human thymus for the first time. These cells represent a potential new target to understand immune diseases and cancer and how to boost the immune system.

Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality. Professor Bernd Rehm and Dr Shuxiong Chen from the Griffith Institute for Drug Discovery (GRIDD) and Griffith’s Centre for Cell Factories and Biopolymers have succeeded in developing a new vaccine modality that is a stable particulate vaccine.